{
  "type": "article",
  "title": "Sudarshan Pharma Stock Jumps After Announcing 9.50% Stake Acquisition in US Biotech Firm",
  "summary": "Sudarshan Pharma Industries shares gained momentum after the company announced plans to acquire a 9.50% stake in US-based MedTherapy Biotechnology.",
  "content": "Shares of small-cap pharmaceutical player Sudarshan Pharma Industries attracted significant market attention during the trading session following a major overseas expansion announcement. The company disclosed plans to acquire a minority stake in an American biotechnology firm to broaden its international footprint.\n\nAcquisition Details and Timeline\nSudarshan Pharma Industries Ltd intends to purchase nearly 24.24 lakh equity shares, representing 9.50 percent of the total issued and outstanding share capital of US-based MedTherapy Biotechnology Inc. The transaction involves a cash investment denominated in US dollars.\n\nThe board of directors approved the proposed transaction, which was formally communicated through an exchange filing on September 5. The final purchase consideration will be determined based on the valuation applicable to MedTherapy at the time of completion. Sudarshan Pharma targets March 31, 2027, to finalize the acquisition, pending regulatory approvals and other standard conditions.\n\nPromoter Investments and Regulatory Compliance\nAlongside the corporate investment, Chairman and Managing Director Hemal Mehta and Joint Managing Director Sachin Mehta are planning individual investments in the biotech firm. Both promoters aim to secure a 1.50 percent stake each in MedTherapy.\n\nThe cross-border investment will proceed under the provisions of the Foreign Exchange Management Act and India's overseas investment framework. According to the company, the transaction qualifies under the Reserve Bank of India's automatic route provided all requisite conditions are satisfied.\n\nOperational Focus of MedTherapy\nMedTherapy Biotechnology operates out of Boston, specializing in advanced cancer cell and gene therapies, including CAR-T cell therapy, which utilizes specially engineered immune cells to combat cancer.\n\nThe firm functions as an integrated contract development and manufacturing organization for these therapies. It maintains a commercial-scale GMP manufacturing facility in New Delhi alongside a technology development centre in Boston.\n\nMarket Performance and Stock Movement\nOn September 7, 2026, Sudarshan Pharma shares traded at Rs 40.85, registering an increase of 3.63 percent, or Rs 1.43, during the session. The stock opened at Rs 40.25, touched an intraday high of Rs 41.39, and recorded a low of Rs 40.25. On the preceding Friday, the stock closed nearly 1 percent higher at Rs 39.42. The company holds a market capitalisation of approximately Rs 984 crore as of September 4.\n\nThe stock has delivered strong returns over multiple timeframes, rising more than 15 percent over the past month and over 52 percent across the last six months. Over a three-year horizon, the small-cap pharmaceutical counter has posted substantial gains for long-term investors, keeping market participants focused on its ongoing developments.\n\nWhat this means for you\nThis cross-border acquisition carries notable implications for market participants and shareholders tracking small-cap pharmaceutical companies.\n\n• Across India: Investors monitoring pharmaceutical equities should evaluate how international expansion plans influence domestic stock valuations and trading volumes.\n• For Shareholders: Existing investors need to track the progress of the deal leading up to the March 2027 completion deadline and subsequent regulatory updates.\n• Financial Considerations: Transactions denominated in US dollars under foreign exchange guidelines expose the process to currency fluctuation risks.\n• Long-term Outlook: Venturing into specialized segments like cell therapy broadens the corporate scope, though minority holding limits direct operational control.\n\nQuestions & Answers\n\n1. Which company is Sudarshan Pharma acquiring a stake in?\nSudarshan Pharma plans to acquire a 9.50% stake in US-based MedTherapy Biotechnology Inc.\n\n2. How many shares are involved in the proposed acquisition?\nThe transaction involves acquiring around 24.24 lakh equity shares of the biotechnology firm.\n\n3. When is the acquisition expected to be completed?\nSudarshan Pharma expects to finalize the acquisition by March 31, 2027.\n\n4. What is MedTherapy Biotechnology's primary area of business?\nThe Boston-based company specializes in cancer cell and gene therapy, including CAR-T cell treatments.\n\n5. Are company promoters participating in the investment?\nChairman and MD Hemal Mehta and Joint MD Sachin Mehta also plan to acquire individual 1.50% stakes in MedTherapy.",
  "url": "https://trendkia.com/en/money/sudarshan-pharma-stock-jumps-after-announcing-9-50-stake-acquisition-in-us-biotech-firm-28942",
  "category": "Money",
  "publishedAt": "2026-09-07",
  "tags": [
    "Sudarshan Pharma",
    "MedTherapy Biotechnology",
    "Stock Market",
    "Pharma Stocks",
    "Biotech",
    "Small Cap"
  ],
  "language": "en",
  "site": "TrendKia"
}